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Abstract
Purpose of Review The purpose of this study was to review
the recent randomised controlled trials of coronary computed
tomography angiography (CCTA) for patients with stable cor-
onary artery disease.
Recent Findings The initial results and subsequent papers
from the SCOT-HEART (Scottish COmputed Tomography
of the HEART) and PROMISE (PROspective Multicentre
Imaging Study for Evaluation of chest pain) trials have shown
that CCTA is a safe and appropriate addition to standard care
or alternative to functional testing. The SCOT-HEART study
showed that CCTA changes diagnoses, improves diagnostic
certainty, changes management, leads to more appropriate use
of invasive coronary angiography, and reduces fatal and non-
fatal myocardial infarction. A meta-analysis of the four
randomised controlled trials showed that CCTA leads to a
major reduction in myocardial infarction in patients with sta-
ble chest pain.
Summary CCTA is now an established technique for the as-
sessment of coronary artery disease. Recent ‘test and treat’
randomised controlled trials have shown that CCTA guided
changes in management can improve clinical outcomes.
Keywords Computed tomography . Chest pain . Angina .
Coronary heart disease
Abbreviations
CCTA Coronary computed tomography angiography
CI Confidence interval
ETT Exercise tollerance test
HR Hazard ratio
ICA Invasive coronary angiography
mSv Millisievert
MPS Myocardial perfusion single photon emission
OR Odds ratio
RACPC Rapid access chest pain clinic
RR Relative risk
Introduction
Coronary computed tomography angiography (CCTA) is now
an established technique for the assessment of patients with
suspected coronary artery disease (CAD). It has an excellent
diagnostic accuracy for the identification of CAD, with a high
negative predictive value [1]. Large-scale registry studies have
shown the prognostic utility of CCTA in the identification of
both obstructive disease and non-obstructive atherosclerotic
plaque. However, recent clinical studies have moved beyond
the assessment of diagnostic accuracy or registry studies. This
review discusses the outcome-based research that has
established the role of CCTA in the assessment of patients
with suspected coronary heart disease.
A normal CCTA is associated with a good prognosis in
large registry studies of patients with suspected CAD [2–4].
Both the presence and the extent of obstructive CAD were
associated with a worsening prognosis in the COronary CT
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Angiography EvaluatioN For Clinical Outcomes: An
InteRnational Multicenter (CONFIRM) registry [5]. In addi-
tion, the extent of non-obstructive coronary artery atheroscle-
rotic plaque was a predictor of mortality in several registry
studies [4, 6, 7] and the use of statin therapy at baseline was
associated with reduced mortality for patients with non-
obstructive CAD in the CONFIRM study [6]. The lack of
randomisation in registry studies means that there is major
confounding by indication, and that they cannot determine
the clinical utility of CCTA or the effect of treatment decisions
based on CCTA results. More recently, several large ‘test and
treat’ randomised controlled trials have been performed to
address these issues, including the PROMISE and SCOT-
HEART studies.
PROMISE
The PROMISE (PROspective Multicentre Imaging Study for
Evaluation of chest pain) trial recruited 10,003 symptomatic
stable outpatients who were due to undergo non-invasive in-
vestigation for suspected CAD [8••]. Participants were
randomised to undergo either anatomical assessment with
CCTA or functional testing with exercise electrocardiography,
stress echocardiography or radionucleotide perfusion imaging
(Table 1).
The mean age of the participants was 61 years, 53% were
female and the pre-test probability of obstructive CAD was
53%. Over one quarter of patients (27%) presented with a
primary symptom other than chest pain, such as breathlessness
or fatigue. The characterisation of chest pain was typical an-
gina for 12%, atypical angina for 78% and non-anginal chest
pain for 11% (Table 2).
The primary outcome of the PROMISE study was a com-
posite of all-cause mortality, myocardial infarction,
hospitalisation for unstable angina and major complications
of cardiovascular procedures or diagnostic testing. At
12 months of follow-up, the risk of death or non-fatal myo-
cardial infarction was lower in the CCTA group than in the
functional imaging group (hazard ratio (HR) 0.66, 95% con-
fidence interval (CI) 0.44–1.00, P = 0.049). However, at
25 months of follow-up, there was no difference in the prima-
ry outcome between the two groups (events 3.3 vs 3.0%, HR
1.04, 95% CI 0.83–1.29, P = 0.75). Thus, PROMISE showed
that CCTA is a safe alternative to functional testing in a low-
risk population with similar outcomes in both groups after
2 years of follow-up.
SCOT-HEART
The SCOT-HEART (Scottish COmputed Tomography of the
HEART) trial randomised 4146 outpatients with suspected
angina due to CAD to standard care or standard care plus
CCTA [9]. Participants were recruited from cardiology outpa-
tient rapid access chest pain clinics (RACPC) and 47% of all
eligible patients were recruited, including patients with atrial
fibrillation, high calcium score and high body mass index
[10••].
The mean age of participants was 57 years, 44% were
female and the pre-test probability of obstructive coronary
heart disease was 47%. The presence of typical angina was
higher in the SCOT-HEART trial as compared to the
PROMISE trial (35 vs 12% of participants). Atypical angina
was the presenting complaint in 24% of patients (cf. 78% in
PROMISE) and 41% (cf. 11%) had non-anginal chest pain
(Table 2).
Table 1 Study design of the four
randomised studies of CCTA PROMISE SCOT-HEART CAPP Min et al.
Recruiting
centres
193 12 1 1
Study
groups
CCTA vs functional testing
(ETT, stress echo or
radionucleotide
perfusion imaging)
CCTA and standard care vs
standard care alone
CCTA vs
ETT
CCTA vs MPS
Primary
endpoint
Composite of all-cause
mortality, myocardial
infarction,
hospitalisation for
unstable angina, and
major complications of
cardiovascular
procedures or diagnostic
testing
Proportion of patients
diagnosed with angina
pectoris secondary to
coronary heart disease at
6 weeks
Difference in
symptoms
from
baseline to
3 months
Angina-specific
health status
Follow-up
duration
(months)
25 20 12 55 days
ETT exercise electrocardiography, echo echocardiography, MPS myocardial perfusion single photon emission
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The primary endpoint of the SCOT-HEART trial was the
certainty of the diagnosis angina pectoris secondary to signif-
icant CAD at 6 weeks (Table 1). At 6 weeks, the diagnosis was
changed in 23% of patients undergoing CCTA compared to
1% in the standard care group (p < 0.0001). CCTA improved
the certainty of the diagnosis for both the presence of CAD
and the diagnosis of angina due to (CAD) (RR 2.56, 95% CI
2.33–2.79, P < 0.0001 and RR 1.79, 95% CI 1.79, 1.62–1.96,
P < 0.001). CCTA increased the frequency of the diagnosis of
CAD (relative risk (RR) 1.09, 95%CI 1.02–1.17, P = 0.0172),
but tended to decrease the frequency of the diagnosis of angi-
na due to significant CAD (RR 0.93, 95% CI 0.85–1.02,
P = 0.1289).
At 1.7 years of follow-up, the CCTA group had a 38%
lower rate of fatal and non-fatal myocardial infarction as com-
pared to the control group, but this difference did not quite
reach statistical significance (26 vs 42, HR 0.62, 95% CI
0.38–1.01, P = 0.0527) [10••]. The overall event rate was
low, similar to the PROMISE study, occurring in just 2% of
participants. However, in a post hoc landmark analysis cen-
sored to the median time of treatment alteration (50 days),
there was a 50% reduction in fatal and non-fatal myocardial
infarction in the CCTA group (17 vs 34, HR 0.50, 95% CI
0.28–0.88, P = 0.020) [11••].
Other Studies and Meta-analysis
There are two other smaller randomised controlled trials
which have recently assessed CCTA in patients with stable
chest pain: the CAPP trial [12•] and a study byMin et al. [13•].
The CAPP trial randomised 500 patients with stable chest
pain who were referred to a RACPC for assessment [12•].
Patients were randomised to either undergo exercise stress
electrocardiogram (ETT) or CCTA (Table 1). The mean age
was 59 years, 45%were female, and the pre-test probability of
significant CAD was 45% in the ETT group and 48% in the
CCTA group (P = 0.34) (Table 2). The primary endpoint was
the difference in symptoms from baseline to 3 months be-
tween the two groups, assessed using the Seattle Angina
Questionnaire. They identified no difference in major adverse
cardiac events between the ETT and CCTA groups.
The study byMin et al. randomised 180 patients with stable
chest pain from cardiology outpatient clinics to undergo
CCTA or myocardial perfusion single photon emission CT
(MPS). [13•] (Table 1) The mean age was 56 years for the
CCTA group and 59 years for the MPS group (P = 0.04), and
44% were female (Table 2). Pre-test probability was not pro-
vided but 32% had typical angina, 23% atypical angina and
27% non-anginal chest pain. The primary endpoint was the
“angina-specific health status”. No patients had a myocardial
infarction or died in either group during the follow-up of
55 days.
A meta-analysis has combined the primary results of
PROMISE, SCOT-HEART, CAPP and the study by Min
et al. [14•]. It identified that compared to standard care, the
use of CCTA was associated with a reduction in the annual
rate of myocardial infarction (rate ratio 0.69, 95% CI 0.49–
0.98, P = 0.038), but there was no difference in all-cause
mortality [14•]. This 31% relative risk reduction in myocardial
infarction occurred with CCTA despite the relatively low rate
of events in the individual studies over a median of 2 years of
follow-up.
Effect of CCTA on Downstream Investigations
In the SCOT-HEART trial, CCTA led to a change in the
planned investigations in 15% of participants, compared to
1% in the standard care group (P < 0.0001) [10••]. For some
participants, planned investigations were cancelled, whilst for
others, new investigations were organised, primarily invasive
coronary angiography (ICA). Overall, the rates of ICA were
similar between groups in the SCOT-HEART study (409 vs
401, P = 0.451). In the study by Min et al., there were also
similar rates of ICA between the CCTA and the MPS groups
[13•]. However, in the PROMISE study, there was an increase
in the number of patients undergoing ICA in the CCTA group
compared to the functional imaging group (12.2 vs 8.1% at
90 days). In both the PROMISE and SCOT-HEART, there
was a reduction in the proportion of patients with normal
ICA [8••, 11••]. In SCOT-HEART, normal or non-
obstructive CAD was identified at invasive coronary angiog-
raphy in 29% of patients in the CT group compared to 41% of
Table 2 Demographic details of
patients recruited into the four
randomised studies of CCTA
PROMISE SCOT-HEART CAPP Min et al.
Number 10,003 4146 448 180
Age (years) 61 57 59 56, 59
Female (%) 53 44 45 44
Pre-test probability (%) 53 47 45, 48 –
Chest pain (%) Typical angina 12 35 34 32
Atypical angina 78 24 8 23
Non-anginal chest pain 11 41 67 27
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patients in the standard care group. Normal coronary arteries
at invasive coronary angiography were identified in SCOT-
HEART in 6.6% of patients in the CT group compared to
19.6% in the standard care group. In PROMISE, normal or
non-obstructive CAD was identified at invasive coronary an-
giography in 28% of patients in the CT group compared to
53% in the control group. This shows that CCTA can be used
to select appropriately patients for ICA and can reduce the
number performed in patients with normal coronary arteries.
Medical Treatment
In the SCOT-HEART study, treatment was changed in 23% of
patients in the CCTA group compared to 5% in the standard
care group (P < 0.0001). This included an increase in the use
of preventative therapies (such as statins, Aspirin and ACE
inhibitors) and decrease in the use of anti-anginal therapies
[10••, 11••]. Min et al. also demonstrated that patients in the
CCTA arm had a subsequent increased use of aspirin and
statins [13•]. CCTA can identify non-obstructive CAD which
other investigations may not identify. It is therefore not sur-
prising, nor a new finding, that CCTA is associated with an
increased use of preventative medications in such patients
[15]. However, a major strength of CCTA is its negative pre-
dictive value and therefore the cessation of unnecessary med-
ications in patients with normal coronary arteries is also an
important outcome after CCTA.
Revascularisation
In the PROMISE trial, there was an increase in the numbers of
patients going on to have revascularisation after invasive cor-
onary angiography in the CCTA group (6.2 vs 3.2%,
P < 0.001) [8••]. In the SCOT-HEART trial, there was also a
statistically non-significant trend towards an increased propor-
tion of revascularisation in the CCTA group (11.2 vs 9.7%,
P = 0.0611) [10••]. Therefore, CCTA can be used to more
appropriately select patients who require further invasive in-
vestigation and treatment.
Cost Analysis
In both the SCOT-HEARTand the PROMISE trials, there was
a small increase in cost in the CCTA group. In the PROMISE
study, the mean cost difference at 90 days was $254 (95%
confidence interval—$634 to $906) [16], and in the SCOT-
HEART study, the difference was $462 (95% confidence in-
terval $303 to $621) at 6 months [11••]. In the PROMISE
study the cost difference was due to the increased use of
ICA and revascularisation in the CCTA group. However, in
the SCOT-HEART study the difference was attributed to the
cost of CCTA itself, as the rate of ICA was not statistically
different between groups [11••]. The cost of CCTA
technology continues to fall and therefore this small difference
in cost between investigation strategies is likely to continue to
decrease in the future.
Symptoms
In SCOT-HEART, PROMISE and CAPP trials, symptoms
improved in both groups of patients indicating general satis-
faction after attendance at the RACPC or cardiology outpa-
tient clinic [10••, 12, 17]. In the SCOT-HEART trial, there was
no difference in symptoms at 6 week between CCTA and
standard care groups [10••]. In the PROMISE trial, there
was no difference in symptoms over 2 years of follow-up
between the CCTA group or functional imaging group [17].
In the study by Min et al., there was no difference in angina
symptoms between groups at 55 days [13•]. However, in the
CAPP study, there was a larger improvement in angina symp-
toms in the CCTA group compared to the ETT group at 3 and
12 months [12•]. This suggests that there may be improved
management and patient satisfaction after CCTA as compared
to ETT. Whilst CCTA undoubtedly improves diagnosis and
allows the optimisation of treatment for patients, CCTA find-
ings can also provide potential uncertainty and anxiety, par-
ticularly for those patients who are subsequently recommend-
ed to start life-long preventative treatments for non-
obstructive CAD. Therefore, it is important to consider poten-
tial patient anxiety when communicating the results of the
CCTA.
Radiation Dose
In the PROMISE trial, the overall radiation exposure was
higher in the CCTA group (mean 12 mSv (milliseverts) vs
10.1 mSv, P < 0.001). However, as 33% of patients in the
functional testing group did not have any radiation exposure
at all, and therefore, the median cumulative radiation exposure
per patient was lower in the CCTA group (10.0 vs 11 mSv). In
the SCOT-HEART trial, the median radiation dose for CCTA
and non-contrast coronary artery calcium score was 4.1 (inter-
quartile range 3.0–5.6) mSv. More than one third of the radi-
ation exposure in the SCOT-HEART trial was attributed to the
coronary artery calcium score. The additional benefit of
performing a non-contrast scan for calcium scoring in patients
who are undergoing CCTA is low, and indeed, in many cases,
this additional examination is not required. The mean radia-
tion dose in the CCTA group of the CAPP trial was 5.37 mSv.
In the study byMin et al., the CCTA group had a significantly
lower radiation dose than the MPS group (7.4 vs 13.3 mSv,
P < 0.001). CCTA can now be performed at a low radi-
ation dose for patients with a range of heart rates and
body size (Fig. 1).
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Plaque Characterisation
In addition to assessing stenosis severity, CCTA can assess the
constituents and morphology of atherosclerotic plaques.
Motoyama et al. identified that the presence of low attenuation
plaque, positive remodelling and spotty calcification were as-
sociated with an increased risk of acute coronary syndrome
[18]. A meta-analysis of subsequent studies found a signifi-
cantly higher risk of acute coronary syndromes in patients
who had high-risk plaque (odds ratio (OR) 12.1, 95% CI
5.24–28.1, P = 0.0001) [19]. However, the use of these plaque
markers in randomised outcome-based research studies have
not yet been assessed.
Functional Assessment
Cardiac CT can assess myocardial perfusion using static or
dynamic techniques with good diagnostic accuracy compared
to other imaging modalities [20]. Computational fluid
dynamic models can estimate pressure and flow within the
coronary arteries. These estimates can be used to calculate
non-invasive fractional flow reserve (FFR). The use of non-
invasive FFR based on CCTA images may reduce the rate of
normal invasive coronary angiograms, lower costs reduce ra-
diation exposure, improved quality of life and improve the
detection of lesions causing ischaemia [21–24].
Conclusion
CCTA is a safe diagnostic test that can be performed at a low
radiation dose and is now widely available. Recent clinical
trials have established the role of CCTA in the assessment of
patients with suspected CAD. The use of CCTA not only
changes the diagnosis but it also alters management that ulti-
mately reduces the future risk of fatal and non-fatal myocar-
dial infarction. National guidelines, such as the UK NICE
guidelines, have recently changed to incorporate CCTA as
Fig. 1 An example of low radiation dose CCTA with comparison to
invasive coronary angiography from the SCOT-HEART study. This 60-
year-old male patient with no previous history of cardiovascular disease
and no cardiovascular risk factors presented with chest pain. CCTA
identified severe disease in the left anterior descending coronary artery
(a), first diagonal (b) and circumflex artery (c) which was confirmed on
invasive coronary angiograph (d). Mild non-obstructive disease was
identified in the right coronary artery (f, g). e Shows a three-
dimensional reconstruction of the heart from the CT. The patient
underwent revascularisation. The total dose length product for CCTA
and calcium scoring CT was 358 mGy cm (5 mSv using the
0.014 mSv/mGy cm conversion factor)
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the first-line test in stable chest pain (discussed by Moss et al.
in another paper in this issue) and other international guide-
lines are likely to follow suit in time.
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